tweenvest

IRulya Therapeutics Inc. (NasdaqCM: IRLA)

Health Care · Biotechnology · US

$39.78

+3.78% today · -88.2% 1Y

Public summary
A free snapshot of IRulya Therapeutics Inc., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

IRulya Therapeutics Inc. (NasdaqCM: IRLA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $40.46M and employs 38 people.

Over the last twelve months the share price has lost 88.2%, trading between 15.10 and 909.98.

Tweenvest scores IRulya Therapeutics Inc. across four factors: quality 37/100, value 69/100. Its strongest factor is value.

IRLA price history

Nov 21, 2025 · 428.00Weekly closes 16.00 – 844.00Nov 12, 2026 · 39.78

Key figures

Market cap
$40.46M
Revenue (TTM)
—
P/E
-0.44
EPS
-204.79
Dividend yield
—
Beta (5Y)
1.79
52-week high
$909.98
52-week low
$15.10
Avg volume (3M)
—
Shares outstanding
1.02M
Employees
38
Next earnings
—

About IRulya Therapeutics Inc.

IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.

ISIN
US22053A3059
Founded
2012
Listed since
May 9, 2019
Exchange
Nasdaq Capital Market
Currency
USD
CompanyMarket capPriceDay
CG Invites Co., Ltd.KOSDAQ: A083790$40.73M₩708.00-6.10%
Sprint Bioscience AB (publ)OM: SPRINT$40.56MSkr3.87+2.38%
PanGen Biotech Inc.KOSDAQ: A222110$40.55M₩4,005.00+0.25%
Aldeyra Therapeutics, Inc.NasdaqCM: ALDX$40.51M$0.67-3.29%
Harvard Apparatus Regenerative Technology Inc.OTCPK: HRGN$40.16M$1.98+9.39%
Cytogen, Inc.KOSDAQ: A217330$40.14M₩2,320.000.00%
Nano Holdings, Inc.TSE: 4571$39.93M¥70.00+2.94%
Alps Group IncNasdaqGM: ALPS$39.27M$1.18+0.43%

Browse every Biotechnology company →